Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) EBIT Margin (2016 - 2025)

Tg Therapeutics has reported EBIT Margin over the past 10 years, most recently at 26.22% for Q4 2025.

  • Quarterly results put EBIT Margin at 26.22% for Q4 2025, up 3233.0% from a year ago — trailing twelve months through Dec 2025 was 20.01% (up 1838.0% YoY), and the annual figure for FY2025 was 20.01%, up 1838.0%.
  • EBIT Margin for Q4 2025 was 26.22% at Tg Therapeutics, up from 18.16% in the prior quarter.
  • Over the last five years, EBIT Margin for TGTX hit a ceiling of 69.22% in Q3 2023 and a floor of 96923.75% in Q4 2022.
  • Median EBIT Margin over the past 5 years was 153.16% (2023), compared with a mean of 8454.13%.
  • Biggest five-year swings in EBIT Margin: soared 22436907bps in 2021 and later tumbled -9291914bps in 2022.
  • Tg Therapeutics' EBIT Margin stood at 4004.61% in 2021, then plummeted by -2320bps to 96923.75% in 2022, then surged by 100bps to 28.39% in 2023, then soared by 78bps to 6.11% in 2024, then soared by 529bps to 26.22% in 2025.
  • The last three reported values for EBIT Margin were 26.22% (Q4 2025), 18.16% (Q3 2025), and 24.69% (Q2 2025) per Business Quant data.